Cystic fibrosis (CF) is among the deadliest and most treatment-challenging respiratory conditions facing patients and their physicians, so what are pharmaceutical scientists doing to make a difference? They are doing what they do best: using knowledge of medications and chemistry and blending it with physiology and anatomy to create a potential “solution.” Pilcer et al.
describe a novel, dried, aerosolized, nanoparticle coformulation of tobramycin and clarithromycin that, in vitro, seems to show great promise in improving pulmonary penetration. The approach of these scientists supports previously published information on the efficacy of combination tobramycin–macrolide efficacy against
In addition, a well-written review of the infectious agents found in CF patients bolsters the ingenuity of combination aminoglycoside–macrolide, even in today's CF population.
Further, this pathway follows the logic of a review of the state of the science for inhaled antibiotics in that although inhaled antibiotics represent a powerful tool to treat patients with CF, better formulations are needed.